The Cost of Waiting: An Endocrinologist's Economic Case for Earlier Metabolic Disease Intervention

In the final episode, 'The Cost of Waiting: An Endocrinologist's Economic Case for Earlier Metabolic Disease Intervention,' Jaime Almandoz, MD explored the following critical questions:

From your experience managing metabolically complex patients, what is the economic argument for payers and employers to cover therapies that address obesity and its downstream consequences at earlier stages of disease?

What data do you think payers should be tracking to truly understand the value of treating metabolic disease, including MASH, earlier and more aggressively?

Almandoz challenged one of the most persistent misconceptions in metabolic disease management, that obesity treatment is primarily about weight loss, arguing instead that obesity is a systemic driver of healthcare utilization across multiple high-cost disease states including type 2 diabetes, cardiovascular disease, osteoarthritis, chronic kidney disease, and MASH, and that by the time a patient develops liver cirrhosis, heart failure, or end-stage kidney disease, the financial and human costs have already become enormous and largely preventable with earlier intervention. He reframed the economic question entirely, urging payers and employers to shift their thinking from what obesity treatment costs today to what future costs are being prevented by treating metabolic disease early. Almandoz closed with a direct message to payers, identifying the outcomes that truly capture the economic value of early metabolic intervention, including incident diabetes, cardiovascular events, progression to advanced liver disease, hospitalizations, disability claims, absenteeism, presenteeism, and total cost of care over time, and cautioning that measuring only annual pharmacy spend misses the vast majority of the economic story.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Insights series on obesity and MASH. Please subscribe to our newsletter for information on upcoming video series.